Drug
ASTX-660 clinical trials
Also written ASTX660 and Tolinapant.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2020 | 4 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 4
Astex Pharmaceuticals, Inc. (3) · Taiho Oncology, Inc. (2) · National Cancer Institute (NCI) (2) · Emory University (1) · Institute of Cancer Research, United Kingdom (1) · Otsuka Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Pembrolizumab (1) · Midazolam (1) · Decitabine and cedazuridine drug combination (1) · Eribulin (1)
Studies
Open first, then newest update. How each study uses ASTX-660 is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)TerminatedPhase 1Taiho Oncology, Inc.NCT05403450Written as Tolinapant
- Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck CancerActive, not recruitingEarly Phase 1Emory UniversityNCT05245682Written as Tolinapant
- ASTEROID: A Trial of ASTX660 in Combination With PembrolizumabActive, not recruitingPhase 1Institute of Cancer Research, United KingdomNCT05082259Written as ASTX660
- Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and LymphomasActive, not recruitingPhase 1/2Taiho Oncology, Inc.NCT02503423Written as ASTX660
- A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell LymphomaTerminatedPhase 1/2Otsuka Pharmaceutical Co., Ltd.NCT04362007Written as ASTX660
- Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast CancerWithdrawnPhase 1National Cancer Institute (NCI)NCT06590558Written as Tolinapant
- Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnPhase 1/2National Cancer Institute (NCI)NCT06393751Written as Tolinapant
- A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate MidazolamCompletedPhase 1Astex Pharmaceuticals, Inc.NCT04411030Written as ASTX660
- Effect of Food on the Pharmacokinetics of ASTX660 in Healthy VolunteersCompletedPhase 1Astex Pharmaceuticals, Inc.NCT04479800Written as ASTX660
- A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)TerminatedPhase 1Astex Pharmaceuticals, Inc.NCT04155580Written as ASTX660
Given in every arm · 1 — ASTX-660 is usual care beside what is tested
Codes
What other systems call ASTX-660 · ClinicalTrials.gg INT001416
- MeSH (NLM) C000710345ASTX-660Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2LHZ9ZC3YOTOLINAPANTConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710345 | ASTX-660 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2LHZ9ZC3YO | TOLINAPANT | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.